Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 2OTHER_GOV 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Diabetes Mellitus, Type 2 1Breast Neoplasms 1

Interventions

pembrolizumab 1032Carboplatin 969Paclitaxel 942Gemcitabine 799Cisplatin 755Docetaxel 698Bevacizumab 638Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 471Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 345Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 289Irinotecan 271130-nm albumin-bound paclitaxel 256Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 217durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × empagliflozin × Clear all
NCT03424005 2026-03-16

Morpheus-panBC

Hoffmann-La Roche

Phase 1/2 Recruiting
792 enrolled
Breast

Breast Neoplasms

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡